GE医疗 GEHC

Peter J. Arduini is the President and Chief Executive Officer and a Director of GE HealthCare Technologies Inc. In December 2022, Mr. Arduini was appointed as President and Chief Executive Officer in connection with the Spin-Off, and he has also served as a member of the Board since the Spin-Off. He served as the President and Chief Executive Officer of GE's healthcare business from January 2022 until December 2022. Previously, Mr. Arduini was the President and Chief Executive Officer of Integra LifeSciences, a global medical technology company, from January 2012 to December 2021. During his tenure as Integra's Chief Executive Officer, the Integra portfolio evolved significantly to a faster growing and more profitable company through multiple acquisitions and a sustainable research and development pipeline. Prior to Integra, Mr. Arduini worked at Baxter Healthcare as President of its Medication Delivery division. Before Baxter Healthcare, he spent 15 years at GE's healthcare business in a variety of leadership roles in the United States and globally, including leading the Computed Tomography and Molecular Imaging business, Healthcare Services and U.S. sales. Mr. Arduini also serves on the board of Bristol Myers Squibb. Mr. Arduini previously served on the board of Integra LifeSciences. Mr. Arduini serves as Director, Advanced Medical Technology Association, and as Director and Chair of Funds Development, The National Italian American Foundation.

Taha Kass-Hout. Dr. Taha Kass-Hout, MD, MS, has served as GE HealthCare's Global Chief Science and Technology Officer since January 2023. Merging his background in interventional cardiology with AI and machine learning, he is driving advancements in AI-based medical imaging, diagnostics, and health system operational efficiency. Prior to his role at GE HealthCare, Dr. Kass-Hout served as Vice President of Machine Learning, Distinguished Engineer, and Chief Medical Officer at Amazon from May 2017 to January 2023, where he led the company's health AI strategy, technologies, and solutions, including Amazon Comprehend Medical, AWS HealthLake, and Amazon Pharmacy. He also played a critical role in establishing Amazon's COVID-19 diagnostics lab, including Amazon's first U.S. FDA authorization for testing its associates globally-later offered to the public for at-home testing. From 2013 to 2016, Dr. Kass-Hout was the first Chief Health Informatics Officer at the FDA, where he championed data transparency through initiatives including openFDA and precisionFDA. Dr. Kass-Hout was appointed as the first Chair of the AdvaMed Digital Health Tech Division Board of Directors, a position he held from October 2023 until January 2026.

James K. Saccaro. Mr. Saccaro has served as our Vice President and Chief Financial Officer since June 2023. Previously, Mr. Saccaro served as the Chief Financial Officer of Baxter International Inc. (NYSE: BAX) (Baxter), a multinational healthcare company, starting in 2015. He held a variety of positions of increasing responsibility at Baxter from 2002 through 2013, including Vice President of Financial Planning and Analysis; Vice President of Finance for Baxter's operations in Europe, the Middle East, and Africa; Vice President of Strategy; and Corporate Vice President and Treasurer. Mr. Saccaro served as Senior Vice President and Chief Financial Officer of Hill-Rom Holdings, Inc. from 2013 to 2014 prior to rejoining Baxter as Special Assistant to the Chief Executive Officer in 2014. Prior to 2002, he held strategy and business development positions at Clear Channel Communications and The Walt Disney Company. On July 21, 2026, James K. (Jay) Saccaro notified GE HealthCare that he will resign as Chief Financial Officer for a role outside of the medical technology industry. Mr. Saccaro's last day at GE HealthCare will be August 14, 2026.

Frank R. Jimenez. Mr. Jimenez has served as our General Counsel and Corporate Secretary since the Spin-Off. He served as the General Counsel of GE's healthcare business from February 2022 until the Spin-Off. Previously, Mr. Jimenez served as Vice President, General Counsel and Corporate Secretary of Raytheon Company, a defense contractor, from January 2015 to April 2020 and, following Raytheon's merger with United Technologies Corporation, as Executive Vice President and General Counsel (April 2020 to December 2021) and Special Advisor to the Chairman and Chief Executive Officer (December 2021 to February 2022) of Raytheon Technologies Corporation, an aerospace and defense company. In prior public company positions, Mr. Jimenez served as General Counsel of Bunge Limited, ITT Corporation, and ITT spin-off Xylem Inc. In prior public service positions, Mr. Jimenez served as General Counsel of the Navy, Deputy General Counsel of the U.S. Department of Defense, Principal Deputy General Counsel of the Navy, Chief of Staff at the U.S. Department of Housing and Urban Development, and Deputy Chief of Staff and Acting General Counsel for former Florida Governor Jeb Bush. He was previously a litigation partner at Steel Hector & Davis LLP (now Squire Patton Boggs LLP). Mr. Jimenez serves on the boards of Huntington Ingalls Industries (NYSE: HII), where he serves on the compensation committee and the governance and policy committee; the Ann & Robert H. Lurie Children's Hospital of Chicago and Medical Center, where he serves on the audit committee; Equal Justice Works, where he serves as Chairman; and the Executive Committee of the Yale Law School Association, where he serves as President. He also serves on the advisory boards of the Columbia University Mailman School of Public Health and the Yale Law School Center for the Study of Corporate Law, as well as on the University of Miami President's Council.

Roland Rott. Mr. Rott has served as our President and Chief Executive Officer, Imaging since July 2024. Prior to that, Mr. Rott served as our Chief Executive Officer, Ultrasound from the Spin-Off to June 2024. He served as Chief Executive Officer, Ultrasound of GE's healthcare business from April 2021 until the Spin-Off. Mr. Rott joined GE's healthcare business in 2011 and held several leadership roles, including in the global Women's Health Ultrasound and Ultrasound IT segments as well as Maternal Infant Care. Before joining GE, Mr. Rott was Managing Director, Europe, the Middle East, and Africa and Asia Pacific, and Executive Board Member of Exact Holding. In his early career, he had an entrepreneurial start, founding and successfully exiting two software companies in Austria.

H. Lawrence Culp, Jr. is the Independent Chairman of GE HealthCare Technologies Inc. and has served as the non-executive Chairman of the Board since the Spin-Off. Mr. Culp joined the GE Board of Directors in April 2018 and was appointed Chief Executive Officer of GE in October 2018. In June 2022, he assumed additional duty as Chief Executive Officer of GE Aerospace and became Chairman and Chief Executive Officer of GE Aerospace when it launched as a public company in April 2024. Mr. Culp also serves on the board of GE Aerospace. Mr. Culp previously served on the boards of Danaher Corporation, GlaxoSmithKline, and T. Rowe Price Group. Mr. Culp spent 25 years at Danaher Corporation, including serving as President and Chief Executive Officer from 2001 to 2014. Mr. Culp joined Danaher in 1990 at Veeder-Root, becoming President in 1993. He was appointed Group Executive and Corporate Officer in 1995, with responsibility for Danaher's Environmental and Electronic Test and Measurement platforms while also serving as President of Fluke and Fluke Networks. He was named Executive Vice President in 1999, Chief Operating Officer in 2000, and President and Chief Executive Officer in 2001. Mr. Culp is a graduate of Washington College and Harvard Business School, and he served as a Senior Lecturer at Harvard Business School from 2015 to 2018. Mr. Culp serves as Member and former Chairman, Board of Visitors & Governors, Washington College, and as Member, Board of Trustees, Wake Forest University.

Ms. Yang has served as a member of our Board since the Spin-Off. Ms. Yang was the General Manager of Amazon Web Services, Healthcare, a provider of cloud computing platforms and services, between May 2020 and September 2022. Prior to this role, she was at Ascension, where she served as Chief Strategy Officer for Population Health and as Co-Lead and then Lead Managing Director of Ascension Holdings International. Ms. Yang previously served as a public company senior executive at The Advisory Board Company, Discovery Inc., and AOL Time Warner. Ms. Yang also served as an appointee in two U.S. presidential administrations in the U.S. Department of State and the Federal Communications Commission. She is Former General Manager, Amazon Web Services, Healthcare . Other Current Public Company Boards: Doximity. Other Positions: Board of Stewardship Trustee, CommonSpirit Health; Advisor, Brighton Park Capital.

On September 22, 2026, the Board of Directors of GE HealthCare Technologies Inc. appointed Pascal Desroches to serve as a director of the Company, effective January 4, 2027. Mr. Desroches has served as CFO of AT&T since 2021 and plans to retire from the company on December 31, 2026. Previously, he served as CFO of WarnerMedia following AT&T's acquisition of Time Warner in 2018, overseeing financial operations, global real estate, and technology across HBO, Turner Broadcasting, and Warner Bros. As CFO of Turner Broadcasting, he played a pivotal role in the spin-off of three multi-billion-dollar subsidiaries: Time Warner Cable, AOL, and Time. Earlier in his career, Mr. Desroches worked at KPMG and the U.S. Securities and Exchange Commission, gaining broad industry and regulatory experience. He serves on the boards of Honeywell Aerospace, where he chairs the audit committee, and the Federal Reserve Bank of Dallas.

Mr. George A. Newcomb was appointed as Chief Accounting Officer of company effective on December 14, 2022. On July 23, 2026, GE HealthCare named George Newcomb, Controller and Chief Accounting Officer, as interim Chief Financial Officer, effective August 14, 2026. Mr. Newcomb will continue to serve as Controller and Chief Accounting Officer. GE HealthCare has commenced a search for a permanent successor. George Newcomb is an accomplished financial professional with more than 38 years' experience in Finance leadership positions at various companies. Mr. Newcomb has served as the Controller of GE HealthCare since February 2016 and was additionally named as Chief Accounting Officer as a part of the spin off from General Electric Company (GE) in 2023. From 1996 to February 2016, he held a variety of finance leadership roles at GE Capital, including as Capital Planning and Finance Readiness Leader of GE Capital Americas (GECA), Controller of GECA, and CFO roles at Bank BPH, GE Capital Equipment Finance, and GE Capital Healthcare Financial Services. Prior to GE Capital, he was a Senior Tax Manager at Arthur Andersen. He has a bachelor's degree in accounting from the Pennsylvania State University and an M.B.A. from New York University's Stern School of Business. Effective September 14, 2026, George A. Newcomb will step down as Interim Chief Financial Officer and remain as Controller and Chief Accounting Officer of the Company.

On August 13, 2026, the Board of Directors of GE HealthCare Technologies Inc. appointed William K. Grogan as Chief Financial Officer, effective September 14, 2026. Mr. Grogan, age 48, has served as Executive Vice President and Chief Financial Officer of Xylem Inc., a global water solutions company, since October 2023. Previously, Mr. Grogan served as Senior Vice President and Chief Financial Officer of IDEX Corporation, a global engineered products company, from January 2017 until September 2023.

Jeannette Bankes. Ms. Bankes has served as our President and Chief Executive Officer, Patient Care Solutions since May 2025. Previously, Ms. Bankes served as President, Global Franchises at Alcon Inc. (NYSE: ALC), a global manufacturer of vision care products and surgical equipment, from March 2019 to April 2025. Ms. Bankes has served on the board of Aurion Biotech, a clinical-stage regenerative medicine company, since February 2025 and served on the board of Atrion Corp. (Nasdaq: ATRI), a manufacturer of medical application products, from September 2023 to August 2024 and on the board of Apollo Endosurgery, Inc. (Nasdaq: APEN), a medical technology company, from April 2022 to April 2023.

The Board of Directors (the Board) of GE HealthCare Technologies Inc. (the Company) appointed Kevin A. Lobo to serve as a director of the Company, effective 13th March 2026. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. Mr. Lobo has served as the Chief Executive Officer of Stryker Corporation since October 2012 and as chair of the Stryker Board of Directors since July 2014. Prior to this, he held leadership positions in Stryker's Orthopedics Group and Neurotechnology and Spine Group. Mr. Lobo's depth of experience includes operations leadership at Johnson & Johnson, including as President of Ethicon Endo Strategy, and Rhone-Poulenc, a chemical and pharmaceutical company. Earlier in his career, he held finance roles of increasing responsibility at KPMG, Unilever and Kraft Canada.

Adam Y. Holton. Mr. Holton has served as our Chief People Officer since June 2024. Previously, Mr. Holton served as Chief People Officer of Amedisys, a home health company, from October 2022 to June 2024. Prior to that role, he served as Chief Human Resources Officer at Numotion, a provider of rehab technology, from February 2019 to October 2022. Mr. Holton also previously worked as Senior Vice President of Human Resources at USAA, a financial services company, and as Chief Human Resources Officer at CHS Inc., a Fortune-100 agricultural cooperative. Earlier in his career, Mr. Holton worked at GE, including GE's healthcare business. He has served on the Board of Sierra Delta since February 2018 and served as Board Chair from November 2018 until November 2023.

Philip Rackliffe. Mr. Rackliffe has served as our President and Chief Executive Officer, Advanced Visualization Solutions since July 2024. Previously, Mr. Rackliffe served as President and Chief Executive Officer of our Image Guided Therapies business from August 2022 to June 2024. From October 2019 to August 2022, Mr. Rackliffe served as the Chief Executive Officer of Centerline Biomedical, a biomedical device and imaging company. He has over 25 years of global experience in medtech, medical device, imaging and pharmaceutical companies, both public and private, including Baxter, Boston Scientific, and Pfizer.

Kevin M. O'Neill. Mr. O'Neill has served as our President and Chief Executive Officer, Pharmaceutical Diagnostics since the Spin-Off. He served as Chief Executive Officer, Pharmaceutical Diagnostics of GE's healthcare business from July 2017 until the Spin-Off and served as President and Chief Executive Officer, GE U.K. and Ireland, from January 2018 until the Spin-Off. From August 2013 to January 2018, he was the Chief Financial Officer of the Life Sciences division of GE's healthcare business. Mr. O'Neill has over 25 years of experience with GE, beginning in the Energy services business in the U.K. and U.S. followed by a series of chief financial officer roles in GE's healthcare business, including in the Life Sciences business, supply chain, Western Europe, and the PDx business. Prior to joining GE, Mr. O'Neill was Financial Controller for Eurostar, the European high-speed train operator.